|
Multi National companies : Recognizing Indian Potential
NASA to collaborate with Indian bio-medical Industry
National Aeronautic and Space Administration (NASA), USA, is looking for collaboration with Indian Industries in order to transfer its spin-off technologies, especially in the bio-medical field, for the benefit of the common man, a NASA scientist has said here. NASA is working on
nano-biotechnologies for the astronauts who will undertake manned Mars Mission 30 years from now.
Baxter to make Indian arm global hub
Baxter India, a wholly-owned subsidiary of US-based Baxter International, is planning to make its Indian operation a sourcing hub for its international pharmaceutical business. In India, the company is positioning itself to be one of the top pharma companies with turnover of over Rs.250 crore. It markets a variety of products used to treat patients with kidney disease, systems for blood collection and component separation, IV infusion systems, pain management products and many other therapeutic systems.
[Ref: Economic Times, dt. 10/06/04]
Becton plans to make India sourcing base
Becton Dickinson India Pvt Ltd, BD’s fully owned Indian subsidiary, has drawn up plans to invest $ 3 million to create facilities for manufacturing auto disable syringes from this year at its existing plant. This would make BD’s Indian facility, put up at Bawal near Rewari in Haryana at an initial outlay of Rs.110 crore, the second auto disable syringe manufacturing unit globally after Spain.
[Ref: The Times of India - 6/9/02]
Pharmaplan to make India SE Asia hub
Pharmaceutical consulting firm Pharmaplan is planning to develop its Indian arm as an official hub for south east Asian countries. "We have recognised the growth potential here and are discussing the possibility of developing Pharma Plan India as the major centre to cater to South East Asia," said George J
Jakobi, MD, Pharmaplan Germany.
Pharma Plan’s activities in India include technical feasibility and conceptual studies, simulation studies to optimise production costs and basic and detailed engineering of complete pharma/biotechnology/ sterile liquids and medical devices, plants and components.
[Ref: Express Pharma Pulse, 6/12/2001]
Technology
BARC develops new technologies for hazardous waste processing
The Bhabha Atomic Research Centre (BARC) has developed new technologies for waste processing at the Waste Immobilization Plants
(WIP). The technologies developed after sustained R&D efforts are planned to be used at the WIPs to enhance the processing capacity. The technologies include ion exchange process for the treatment of Intermediate Level Waste
(ILW), Advanced vitrification system for the treatment of High Level Waste (HLW) and a demonstration Facility for actinide partitioning.
[Ref: Chronicle Pharmabiz, Aug. 7, 2003]
Identified Gaps
India needs 35,000 dialysis machines, it has only 1,000
It is a country where an estimated 20 lakh suffer kidney afflictions every year, of which, 10% are put on dialysis or need to have their kidney transplanted. According to
nephrologists, these numbers are alarmingly doubling at the turn of each year. It is a nation, whose healthcare centers put
together could be barely equipped with 1,000 dialysis machines, when at least 35,000 are required to tackle what can be described as a frightening scourge.
"In Singapore, Malaysia or the West, even dialysis patients lead normal lives and survive 10 to 20 years. This is largely because of government funded schemes and insurance cover. Singapore is smaller than
Chennai. Yet, it has 38
dialysis centers each armed with 32 machines," Dr. Ravichandran said. ‘Delinked centres’ could be one way of countering this predicament, according to him. A dialysis entails half the cost at a delinked center because it is not saddled with a hospital’s or clinic’s extraneous overheads.
(Ref: The Economic Times, June 4, 2001)
* * * * * * * * * * * * * * * * *
* *
|
